Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR), is soliciting proposals under the Rapid Response Partnership Vehicle (RRPV) Consortium to support the development of investigational vaccines targeting the Bundibugyo Ebola virus (BDBV). The project aims to leverage the VSV vaccine platform, noted for its effectiveness in previous Ebola outbreaks, to advance vaccine candidates from manufacturing process development through production of cGMP Phase 1 clinical trial material, with an initial goal of up to 10,000 doses. The effort also includes early regulatory engagement to guide nonclinical studies essential for investigational new drug (IND) submissions to the FDA, conducting a Phase 1 safety and immunogenicity trial, and the potential option to produce up to 100,000 doses. The overarching objectives are to produce cGMP clinical trial material that meets regulatory standards for use in clinical trials addressing the ongoing 2026 BDBV outbreak and to identify promising vaccine candidates for further development. Proposals must demonstrate how prior platform knowledge and efficiencies will be utilized to expedite manufacturing and regulatory processes. The solicitation was posted on June 11, 2026, with questions due by June 16, and proposal submissions due by June 26, 2026. The work will be performed in Washington, D.C., and the solicitation is managed by BARDA with designated points of contact available for inquiries.
General Info
Agency
NAICS
Place of Performance
Washington, DC, 20024, USASet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows:
The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks.
Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10,000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical. The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100,000 doses of cGMP CTM.
The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development.
Please see the attachments for more information.
Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern.
Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/